Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 301–400 of 1,001
van Asseldonk, E. J. P., Stienstra, R., Koenen, T. B., Joosten, L. A. B., Netea, M. G., & Tack, C. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2992 · Cited by 155
Prediabetes and associated disorders
Buysschaert, M., Medina, J. L., Bergman, M., Shah, A., & Lonier, J. (2014) · Endocrine · doi:10.1007/s12020-014-0436-2 · Cited by 183
Liu, X., Zheng, P., Wang, X., Dai, G., Cheng, H., Zhang, Z., Hua, R., Niu, X., Shi, J., & An, Y. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt446 · Cited by 157
Mechanisms of obesity and related pathology: linking immune responses to metabolic stress
Karalis, K. P., Giannogonas, P., Kodela, E., Koutmani, Y., Zoumakis, M., & Teli, T. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07304.x · Cited by 160
Austin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
“[97] Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al.”
BackgroundAdvances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
Adipose Tissue Inflammation in the Pathogenesis of Type 2 Diabetes
Kohlgruber, A. C., & Lynch, L. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0670-x · Cited by 174
Rheumatoid arthritis, insulin resistance, and diabetes
Nicolau, J., Lequerré, T., Bacquet, H., & Vittecoq, O. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2016.09.001 · Cited by 178
Hypothalamic inflammation: a double‐edged sword to nutritional diseases
Cai, D., & Liu, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06388.x · Cited by 159
Cucak, H., Grunnet, L. G., & Rosendahl, A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0213075 · Cited by 154
New mechanisms of metformin action: Focusing on mitochondria and the gut
Hur, K. Y., & Lee, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12328 · Cited by 161
Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity
Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H., & Bartfai, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.004 · Cited by 160
Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer
Dinarello, C. A., Fossati, G., & Mascagni, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00116 · Cited by 159
Biochemical Regulation of Sleep and Sleep Biomarkers
Clinton, J. M., Davis, C. J., Zielinski, M. R., Jewett, K. A., & Krueger, J. M. (2011) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.1360 · Cited by 159
Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus
Akash, M. S. H., Shen, Q., Rehman, K., & Chen, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23057 · Cited by 170
The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
Kim, Y. G., Kim, S.-M., Kim, K.-P., Lee, S.-H., & Moon, J.-Y. (2019) · Cells · doi:10.3390/cells8111389 · Cited by 150
Toll-like receptors regulate B cell cytokine production in patients with diabetes
Jagannathan, M., McDonnell, M., Liang, Y., Hasturk, H., Hetzel, J., Rubin, D., Kantarci, A., Van Dyke, T. E., Ganley-Leal, L. M., & Nikolajczyk, B. S. (2010) · Diabetologia · doi:10.1007/s00125-010-1730-z · Cited by 156
Gao, M., Ma, Y., & Liu, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119784 · Cited by 170
Interleukin-1, inflammasomes and the skin
Feldmeyer, L., Werner, S., French, L. E., & Beer, H. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.04.008 · Cited by 174
Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice
Aouadi, M., Tencerova, M., Vangala, P., Yawe, J. C., Nicoloro, S. M., Amano, S. U., Cohen, J. L., & Czech, M. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300492110 · Cited by 147
Role of T Cells in Malnutrition and Obesity
Gerriets, V. A., & MacIver, N. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00379 · Cited by 145
Deregulated inflammasome signaling in disease
Lamkanfi, M., Walle, L. V., & Kanneganti, T. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01042.x · Cited by 155
Free radicals and male reproduction.
Agarwal, A. K., & Allamaneni, S. S. R. (2011) · PubMed · Cited by 163
Goldbach‐Mansky, R. T., & Kastner, D. L. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.016 · Cited by 172
Elevations in the Fasting Serum Proinsulin–to–C-Peptide Ratio Precede the Onset of Type 1 Diabetes
Sims, E. K., Chaudhry, Z., Watkins, R., Syed, F., Blum, J., Ouyang, F., Perkins, S. M., Mirmira, R. G., Sosenko, J., DiMeglio, L. A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2849 · Cited by 150
IL-1 family cytokines in inflammation and immunity
Garlanda, C., Ceglie, I. D., & Jaillon, S. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01358-8 · Cited by 170
Immune System: An Emerging Player in Mediating Effects of Endocrine Disruptors on Metabolic Health
Bansal, A., Henao-Mejia, J., & Simmons, R. A. (2018) · Endocrinology · doi:10.1210/en.2017-00882 · Cited by 152
A Genomic Approach to Human Autoimmune Diseases
Pascual, V., Chaussabel, D., & Banchereau, J. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101221 · Cited by 146
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
Mirea, A.-M., Tack, C. J., Chavakis, T., Joosten, L. A. B., & Toonen, E. J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.005 · Cited by 144
B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance
Winer, D. A., Winer, S., Chng, M. H. Y., Shen, L., & Engleman, E. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1486-y · Cited by 142
Goldbach‐Mansky, R. T. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04533.x · Cited by 155
HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus
Kruit, J. K., Brunham, L. R., Verchere, C. B., & Hayden, M. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328339387b · Cited by 145
Nov, O., Shapiro, H., Ovadia, H., Tarnovscki, T., Dvir, I., Shemesh, E., Kovsan, J., Shelef, I., Carmi, Y., Voronov, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053626 · Cited by 147
Innate immune activation in obesity
Lumeng, C. N. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.002 · Cited by 142
Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway
Peiró, C., Romacho, T., Azcutia, V., Villalobos, L. A., Fernández, E., Bolaños, J. P., Moncada, S., & Sánchez‐Ferrer, C. F. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0397-2 · Cited by 159
Blocking interleukin-1β in acute and chronic autoinflammatory diseases
Dinarello, C. A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02313.x · Cited by 164
Cytokines in immune function and sleep regulation
Krueger, J. M., Majde, J. A., & Rector, D. M. (2011) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52006-7.00015-0 · Cited by 134
“IL-1RA reduces fatigue (Omdal and Gunnarsson, 2005) and improves pancreatic beta cell function (Larsen et al., 2007).”
Stanton, M. C., Chen, S.-C., Jackson, J. V., Rojas-Triana, A., Kinsley, D., Cui, L., Fine, J. S., Greenfeder, S., Bober, L. A., & Jenh, C.-H. (2011) · Journal of Inflammation · doi:10.1186/1476-9255-8-8 · Cited by 138
“type 2 diabetes, the use of Anakinra (IL-1Ra) improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation (CRP, IL-6) [ 19 ].”
BackgroundO’Neill, C. M., Lu, C. Y., Corbin, K. L., Sharma, P. R., Dula, S. B., Carter, J. D., Ramadan, J. W., Xin, W., Lee, J. K., & Nunemaker, C. S. (2013) · Endocrinology · doi:10.1210/en.2012-2138 · Cited by 153
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
“Interestingly, a recent controlled study on the use of a recombinant human interleukin-1-receptor antagonist in diabetes reported improvements in glycaemic status, beta cell secretory function and markers of systemic inflammation [ 90 ].”
BackgroundDiabetes and ageing‐induced vascular inflammation
Assar, M. E., Angulo, J., & Rodríguez‐Mañas, L. (2015) · The Journal of Physiology · doi:10.1113/jp270841 · Cited by 152
Rissanen, A., Howard, C. P., Botha, J., Thuren, T., & for the Global Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01637.x · Cited by 140
Innate Immune Cells in the Adipose Tissue in Health and Metabolic Disease
Michailidou, Z., Gomez-Salazar, M. A., & Alexaki, V. I. (2021) · Journal of Innate Immunity · doi:10.1159/000515117 · Cited by 158
Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306799110 · Cited by 137
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Winer, S., & Winer, D. A. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.110 · Cited by 135
Inflammation in obesity-related diseases
O’Rourke, R. W. (2008) · Surgery · doi:10.1016/j.surg.2008.08.038 · Cited by 161
Diabetes and Sepsis: Risk, Recurrence, and Ruination
Frydrych, L. M., Fattahi, F., He, K., Ward, P. A., & Delano, M. J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00271 · Cited by 158
Chaurasia, S. S., Lim, R. R., Parikh, B. H., Wey, Y. S., Tun, S. B. B., Wong, T. Y., Luu, C. D., Agrawal, R. V., Ghosh, A., Mortellaro, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21198-z · Cited by 148
Macrophages and islet inflammation in type 2 diabetes
Eguchi, K., & Manabe, I. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12168 · Cited by 135
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus
Peiró, C., Lorenzo, Ó., Carraro, R., & Sánchez‐Ferrer, C. F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00363 · Cited by 160
“An improvement of several markers of glucose metabolism, such as reduction in HbA1c and an increased C-peptide secretion were obtained, together with the reduction of systemic inflammatory markers, such as CRP and IL-6 levels (Larsen et al., 2007).”
BackgroundImmunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M., Lafdil, F., Kisseleva, T., Szabo, G., & Gao, B. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 137
Ruscitti, P., Masedu, F., Alvaro, S., Airò, P., Battafarano, N., Cantarini, L., Cantatore, F. P., Carlino, G., D'Abrosca, V., Frassi, M., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002901 · Cited by 135
Romacho, T., Valencia, I., Ramos-González, M., Vallejo, S., López‐Esteban, M., Lorenzo, Ó., Cannata, P., Romero, A., Hipólito‐Luengo, Á. S., Gómez-Cerezo, J. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62190-w · Cited by 146
Poulsen, M. M., Fjeldborg, K., Ørnstrup, M. J., Kjær, T. N., Nøhr, M. K., & Pedersen, S. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.024 · Cited by 143
Interleukin-1ß induces the novel adipokine chemerin in adipocytes in vitro
Kralisch, S., Weise, S., Sommer, G., Lipfert, J., Lössner, U., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.02.010 · Cited by 138
The Interplay between Obesity and Inflammation
Săvulescu-Fiedler, I., Mihalcea, R., Dragosloveanu, Ş., Scheau, C., Baz, R. O., Căruntu, A., Scheau, A.-E., Căruntu, C., & Benea, S. N. (2024) · Life · doi:10.3390/life14070856 · Cited by 161
“On the other hand, blocking IL-1 β via antagonists in type 2 DM or obesity showed a significant reduction in systemic inflammation [109–111].”
BackgroundCarstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G. (2010) · Diabetes · doi:10.2337/db09-1199 · Cited by 137
Liu, B., Li, X., Yu, H. V., Shi, X., Zhou, Y., Alvarez, S., Naldrett, M. J., Kachman, S. D., Ro, S., Sun, X., et al. (2021) · Theranostics · doi:10.7150/thno.60265 · Cited by 142
Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes
Barry, J. C., Shakibakho, S., Durrer, C., Simtchouk, S., Jawanda, K. K., Cheung, S. T., Mui, A. L., & Little, J. P. (2016) · Scientific Reports · doi:10.1038/srep21244 · Cited by 131
Qiao, Y.-C., Shen, J. X., He, L., Hong, X., Tian, F., Pan, Y.-H., Liang, L., Zhang, X., & Zhao, H. (2016) · Journal of Diabetes Research · doi:10.1155/2016/3694957 · Cited by 147
Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease
Donath, M. Y., Meier, D. T., & Böni-Schnetzler, M. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00002 · Cited by 124
Self-citationRole of interleukins in obesity: implications for metabolic disease
Febbraio, M. A. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.02.004 · Cited by 147
Disease-associated amyloid and misfolded protein aggregates activate the inflammasome
Masters, S. L., & O'Neill, L. A. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.005 · Cited by 145
Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes
Bowker, N., Shah, R. L., Sharp, S. J., Luan, J., Stewart, I. D., Wheeler, E., Ferreira, M. A. R., Baras, A., Wareham, N. J., Langenberg, C., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103062 · Cited by 142
“While small scale clinical trials had provided initial supportive evidence of possible benefit, [1,17] this notion has been strongly challenged by the negative findings of the Canakinumab Anti-inflammatory Thrombosis Outcome Study [18,19] (CANTOS).”
Result(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00034-0 · Cited by 133
Schulte, D. M., Müller, N., Neumann, K., Oberhäuser, F., Faust, M., Güdelhöfer, H., Brandt, B., Krone, W., & Laudes, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032437 · Cited by 131
Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome
Mitroulis, I., Skendros, P., & Ritis, K. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.005 · Cited by 149
Jin, T., Song, Z., Weng, J., & Fantus, I. G. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00285.2017 · Cited by 127
Interleukin-1 beta targeted therapy for type 2 diabetes
Maedler, K., Dharmadhikari, G., Schumann, D., & Størling, J. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903136688 · Cited by 148
Let thy food be thy medicine….when possible
Witkamp, R. F., & van Norren, K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.026 · Cited by 145
Bhansali, A., Upreti, V., Khandelwal, N., Marwaha, N., Gupta, V., Sachdeva, N., Sharma, R. R., Saluja, K., Dutta, P., Walia, R., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0164 · Cited by 129
Amyot, J., Semache, M., Ferdaoussi, M., Fontés, G., & Poitout, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036200 · Cited by 127
Inflammation as a risk factor and target for therapy in chronic kidney disease
Miyamoto, T., Carrero, J. J., & Stenvinkel, P. (2011) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e32834ad504 · Cited by 128
Prattichizzo, F., De Nigris, V., La Sala, L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1810327 · Cited by 129
Ruscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V, Berardicurti, O., Carubbi, F., Ciccia, F., Alvaro, S., Triolo, G., & Giacomelli, R. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12667 · Cited by 126
MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage
Sousa-Victor, P., Neves, J., Cedron-Craft, W., Ventura, P. B., Liao, C.-Y., Riley, R. R., Soifer, I., van Bruggen, N., Kolumam, G. A., Villeda, S. A., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0023-6 · Cited by 130
Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity?
Bing, C. (2015) · Adipocyte · doi:10.4161/21623945.2014.979661 · Cited by 127
Nąckiewicz, D., Dan, M., He, W., Kim, R., Salmi, A., Rütti, S., Westwell-Roper, C. Y., Cunningham, A. M., Speck, M., Schuster, C., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3249-1 · Cited by 132
Self-citationProinflammatory cytokine interleukin-1β suppresses cold-induced thermogenesis in adipocytes
Goto, T., Naknukool, S., Yoshitake, R., Hanafusa, Y., Tokiwa, S., Li, Y., Sakamoto, T., Nitta, T., Kim, M., Takahashi, N., et al. (2015) · Cytokine · doi:10.1016/j.cyto.2015.11.001 · Cited by 135
“Consistent with this, clinical trials have shown that inhibition of IL-1b signaling by anakinra (a recombinant human IL-1Ra) leads to a sustained reduction in systemic inflammation and amelioration of symptoms of type 2 diabetes [30].”
MethodAn Expanding Role for Interleukin-1 Blockade from Gout to Cancer
Dinarello, C. A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00232 · Cited by 120
Galea, J. P., Ogungbenro, K., Hulme, S., Greenhalgh, A. D., Aarons, L. J., Scarth, S., Hutchinson, P. J., Grainger, S., King, A. T., Hopkins, S. J., et al. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.103 · Cited by 128
Skyler, J. S., Fonseca, V. A., Segal, K. R., & Rosenstock, J. (2015) · Diabetes Care · doi:10.2337/dc14-2830 · Cited by 118
“inflammatory effect of rexlemestrocel-L resulting in improved glycemic control is suggested by similar mild effects reported with canakinumab and anakinra (26,27).”
ResultNovel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus
Akinkuolie, A. O., Pradhan, A. D., Buring, J. E., Ridker, P. M., & Mora, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305635 · Cited by 124
Fenini, G., Grossi, S., Contassot, E., Biedermann, T., Reichmann, E., French, L. E., & Beer, H.-D. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.07.016 · Cited by 125
“DISCUSSION By inducing inflammation, inflammasomes play a fundamental role in immunity and in many different common (auto)inflammatory diseases, ranging from diabetes to atherosclerosis (Larsen et al., 2007; Ridker et al., 2017; Strowig et al., 2012).”
BackgroundImmunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases
Jennings, G. T., & Bachmann, M. F. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061008-103129 · Cited by 139
Vallejo, S., Rosas, E. P., Romacho, T., Villalobos, L. A., Peiró, C., & Sánchez‐Ferrer, C. F. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0158-z · Cited by 125
Rovira‐Llopis, S., Apostolova, N., Bañuls, C., Muntané, J., Rocha, M., & Víctor, V. M. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7313 · Cited by 133
“Therefore, IL-1 b is a key target for the control and modulation of type 2 diabetes (162).”
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
Furst, D. E., Keystone, E. C., Fleischmann, R., Mease, P. J., Fc, B., Smolen, J. S., Kalden, J. R., Braun, J., Bresnihan, B., Burmester, G. R., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123885 · Cited by 146
Type 2 diabetes mellitus—an autoimmune disease?
Velloso, L. A., Eizirik, D. L., & Cnop, M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.131 · Cited by 133
Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity
Meier, D. T., Souza, J. D. P., & Donath, M. Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06306-1 · Cited by 133
Self-citationNov, O., Kohl, A., Lewis, E. C., Bashan, N., Dvir, I., Ben-Shlomo, S., Fishman, S., Wueest, S., Konrad, D., & Rudich, A. (2010) · Endocrinology · doi:10.1210/en.2010-0340 · Cited by 116
The NLRP3 Inflammasome as a Novel Player of the Intercellular Crosstalk in Metabolic Disorders
Benetti, E., Chiazza, F., Patel, N. S. A., & Collino, M. (2013) · Mediators of Inflammation · doi:10.1155/2013/678627 · Cited by 120
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A., Galon, J., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 119
Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
Seok, J. K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01307-9 · Cited by 131
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
Fürst, D. E., Keystone, E. C., Braun, J. M., Fc, B., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201036 · Cited by 131
Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
Chamberlain, J., Francis, S., Brookes, Z., Shaw, G., Graham, D., Alp, N. J., Dower, S., & Crossman, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005073 · Cited by 114
Regulating metabolic inflammation by nutritional modulation
Charles‐Messance, H., Mitchelson, K. A. J., Castro, E. D. M., Sheedy, F. J., & Roche, H. M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.013 · Cited by 133
Perkisas, S., & Vandewoude, M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2743 · Cited by 120
Glucose regulation of islet stress responses and β‐cell failure in type 2 diabetes
Jonas, J. C., Bensellam, M., Duprez, J., Elouil, H., Guiot, Y., & Pascal, S. M. A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01112.x · Cited by 118
“Despite these negative studies, the beneficial effect of the recombinant IL1-receptor antagonist anakinra on glucose tolerance in human T2D indicates that, in some patients at least, circulating or locally produced IL1β contributes to glucose intolerance [32,86] (Fig.”
Background
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.